SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as market sentiment shifts due to positive developments, including institutional partnerships and the potential for a more favorable regulatory landscape. Community members are actively debating the token's long-term valuation, with many highlighting its quantum-resistant technology and perceived undervaluation despite recent price volatility.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest and social media activity driven by optimism surrounding its pivot into pharmaceutical manufacturing and the potential for domestic supply chain contracts. The community remains focused on upcoming earnings reports and active discussions regarding the company's valuation, asset base, and long-term turnaround strategy.

Mezo is the onchain Bitcoin banking platform owned by its users. Users can access self-service Bitcoin finance without interacting with loan officers, undergoing credit checks, or observing operational hours. It’s just you, your Bitcoin, and permissionless access to financial services 24/7.  Traditional banks profit from your deposits while charging you for access to your own money. Two-sided lending markets trap you with 8-9% variable rates that can spike unpredictably, especially in decentralized financial systems. Both systems put middlemen between you and your wealth.  Mezo eliminates them all, giving you the power to manage your finances intelligently on your own terms.  Deposit Bitcoin as collateral, mint MUSD (a dollar-pegged stablecoin), and use it however you need. Your Bitcoin stays yours while MUSD provides you with instant liquidity. Fixed rates start as low as 1% and stay fixed for the entire life of the loan.  This is self-service banking with complete autonomy. Unlike any traditional banking experience, there are no minimum payments, set repayment schedules, or penalties for early repayment. Close your position tomorrow or keep it open for years.  It’s your Bitcoin and your decision on what to do with it.

MEZO

MEZO is gaining significant traction following a new listing on Coinbase and a strategic partnership with Aerodrome Finance aimed at bolstering liquidity within the Bitcoin DeFi ecosystem. Market participants are actively discussing the token's utility for gas fees and governance, while simultaneously monitoring reported buying limitations on trading platforms as the asset enters its initial price discovery phase.

Fidelity Covington Trust - Fidelity MSCI Communication Services Index ETF

Fidelity MSCI Communication Services Index ETF

Investors are closely monitoring this ETF as the broader communication services sector experiences volatility driven by heavy exposure to major tech earnings and evolving AI infrastructure investments. Discussion remains centered on the fund's long-term potential as a diversified play on top-tier media and technology giants within an uncertain macro environment.

IDEX

IDEX is seeing heightened volatility and investor chatter as traders debate whether current consolidation levels will spark a breakout or lead to further downside. The community is actively discussing potential technical setups, upcoming liquidity initiatives, and the coin's history of sharp price movements, driving divided sentiment between those looking to buy the dip and others anticipating a traditional pump-and-dump cycle.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing heightened community interest driven by anticipation of upcoming earnings and potential major orders, with investors closely watching for a transition from evaluation phases to high-volume production for AI data center infrastructure. The conversation remains split between high conviction in the stock's role as a critical gatekeeper for AI chip reliability and skepticism regarding its ability to convert long-standing product interest into consistent, profitable revenue growth.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as investors weigh its potential as a vertically integrated photonics player against broader market volatility and concerns over dilution, with the community actively debating the company's long-term commercialization strategy versus short-term price pressure. Discussions are heavily focused on the viability of its proprietary TFLN-based hardware and the ongoing tension between its high-cash balance sheet and persistent revenue growth challenges.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is trending as investors focus on its recent commercial milestones, including a signed purchase order with a Latin American public safety organization for drone and sensing technologies. The community is actively discussing potential for a short squeeze due to the stock's low float, institutional ownership, and the company's aggressive stance against suspected predatory naked short selling.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is currently trending as community members speculate on a potential short squeeze and upcoming partnership rumors following news of a token buyback. Investors are actively debating the token's long-term utility versus its recent price volatility, with many monitoring volume spikes for a possible breakout from its current micro-cap levels.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is generating significant buzz as investors anticipate clinical data readouts at the upcoming ASH conference, fueling speculation that positive results could lead to a near-term buyout by Incyte. The community is actively debating the company's valuation relative to oncology peers, with many highlighting its two approved drugs and strong commercial momentum as key factors supporting a potential acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +91.67% and -28.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -45.28% and -45.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +39.91% and -21.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of +26.32% and +365.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates

Arcellx (ACLX) delivered earnings and revenue surprises of -3.13% and -66.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +18.18% and -103.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.

Dare Bioscience Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.33	--	--	N/A
Q4 '25	-$0.44	$0.03	106.82%	BEAT
Q3 '25	-$0.38	-$0.28	27.09%	BEAT
Q2 '25	-$0.58	-$0.45	22.46%	BEAT
Q1 '25	-$0.58	-$0.50	13.79%	BEAT

DARE
Dare Bioscience Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest DARE News

DAREDare Bioscience Inc